Showing results (11-20 of 35) with videos related to
Sort By:
Pageof 4
The Journal of Pharmacology and Experimental Therapeutics|December 2, 2011
Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse modelsShinji Yamazaki, Paolo Vicini, Zhongzhou Shen, et al.Journal of Pharmaceutical Sciences|March 12, 2005
Simple strategies for reducing sample loads in in vitro metabolic stability high-throughput screening experiments: a comparison between traditional, two-time-point and pooled sample analysesSabrina X Zhao, Darcy Forman, Nora Wallace, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 22, 2022
Human and nonclinical disposition of [<sup>14</sup>C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infectionRaju Subramanian, John Ling, Jianhong Wang, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 3, 2008
Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse modelsShinji Yamazaki, Judith Skaptason, David Romero, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 5, 2013
In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactionsEric L Reyner, Samantha Sevidal, Mark A West, et al.Molecular Pharmaceutics|November 13, 2025
Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel OxidationSandhya Subash, Dilip K Singh, S Cyrus Khojasteh, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 30, 2015
In Vitro Kinetic Characterization of Axitinib MetabolismMichael A Zientek, Theunis C Goosen, Elaine Tseng, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 11, 2014
Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humansBill J Smith, Yazdi Pithavala, Hai-Zhi Bu, et al.Journal of Clinical Pharmacology|March 21, 2009
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approachesNatilie A Hosea, Wendy T Collard, Susan Cole, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 2020
Regional Proteomic Quantification of Clinically Relevant Non-Cytochrome P450 Enzymes along the Human Small IntestineHaeyoung Zhang, Chris Wolford, Abdul Basit, et al.Pageof 4